CYP2C19基因多态性在抗血小板治疗中的研究进展

The progress in research of CYP2C19 gene polymorphism in antiplatelet therapy

CYP2C19基因多态是影响氯吡格雷代谢的主要遗传因素,导致氯吡格雷的疗效个体差异很大。携带CYP2C19功能缺失等位基因的PCI术后患者,服用氯吡格雷会增加冠脉血栓事件的风险。通过血小板基因检测,确定哪些患者适合更换新型P2Y12受体抑制剂(普拉格雷或替格瑞洛),临床意义重大。本研究概述了P2Y12受体抑制剂的个体差异及血小板基因检测对接受PCI患者的指导价值。

CYP2C19 gene polymorphism is the main genetic factor affecting the metabolism of clopidogrel,which leads to the individual difference in the efficacy of clopidogrel.The presence of a CYP2C19 loss-of-function allele is associated with an increased risk of atherothrombotic events among clopidogrel treated patients undergoing PCI.According to the platelet genetic testing,it can be determine which patients are suitable to replace the new P2Y12 receptor inhibitors(prasugrel or ticagrelor).This study summarized the individual differences of P2Y12 receptor antagonists and the guiding value of platelet gene testing for PCI patients.